Literature DB >> 18472000

Association of tumour necrosis factor alpha (TNF-alpha) polymorphisms with Graves' disease: A meta-analysis.

Ni Li1, Zongguang Zhou, Xuyang Liu, Yi Liu, Junjun Zhang, Liang Du, Maoling Wei, Xiaoming Chen.   

Abstract

OBJECTIVE: To quantitatively summarize the association between tumour necrosis factor alpha (TNF-alpha) gene polymorphisms and Graves' disease. DESIGN AND METHODS: Relevant studies were identified from the following electronic databases: Cochrane Library, MEDLINE, EMBASE and Chinese Bio-medicine Database. A meta-analysis of relevant studies was performed.
RESULTS: This meta-analysis included 10 case-control studies, which included 2271 Graves' disease cases and 2633 controls. The combined results based on all studies showed that there was significant difference in genotype distribution (-308A/G; -308G/G; -863C/C; -863C/A; -1031C/T) between Graves' disease and controls. When stratifying for race, statistically significant results were observed in three genotype distribution (-863C/C; -863C/A; -1031C/T) between Graves' disease and controls among Asians. Statistically significant results were observed in only two genotype distribution (-308A/G; -308G/G) between Graves' disease and controls among Caucasians.
CONCLUSIONS: This meta-analysis suggests that TNF-alpha gene polymorphisms at positions -308 (G-308A), -863 (C-863A), and -1031 (T-1031C) were associated with Graves' disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472000     DOI: 10.1016/j.clinbiochem.2008.04.014

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  9 in total

1.  NF-κB in DCs: it takes effort to be immature.

Authors:  Rémi J Creusot
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

2.  Graves' disease and gene polymorphism of TNF-α, IL-2, IL-6, IL-12, and IFN-γ.

Authors:  Mehdi Anvari; Omid Khalilzadeh; Alireza Esteghamati; Fatemeh Momen-Heravi; Mahdi Mahmoudi; Shadi Abdar Esfahani; Armin Rashidi; Aliakbar Amirzargar
Journal:  Endocrine       Date:  2010-03-05       Impact factor: 3.633

3.  Interaction of HLA-DRB1*1501 and TNF-Alpha in a Population-based Case-control Study of Multiple Sclerosis.

Authors:  Dhelia M Williamson; Ruth Ann Marrie; Allison Ashley-Koch; Glen A Satten
Journal:  Immunol Infect Dis       Date:  2013-09

4.  Tumor necrosis factor alpha 308 G/A polymorphism and Guillain-Barré syndrome risk.

Authors:  Hong Jiao; Weizhi Wang; Huabing Wang; Yun Wu; Lihua Wang
Journal:  Mol Biol Rep       Date:  2011-05-22       Impact factor: 2.316

Review 5.  Clinical implications of shared genetics and pathogenesis in autoimmune diseases.

Authors:  Alexandra Zhernakova; Sebo Withoff; Cisca Wijmenga
Journal:  Nat Rev Endocrinol       Date:  2013-08-20       Impact factor: 43.330

6.  Nuclear factor-κB1 controls the functional maturation of dendritic cells and prevents the activation of autoreactive T cells.

Authors:  Dilan Dissanayake; Håkan Hall; Nancy Berg-Brown; Alisha R Elford; Sara R Hamilton; Kiichi Murakami; Leslie Summers Deluca; Jennifer L Gommerman; Pamela S Ohashi
Journal:  Nat Med       Date:  2011-11-13       Impact factor: 53.440

7.  Involvement of functional polymorphisms in the TNFA gene in the pathogenesis of autoimmune thyroid diseases and production of anti-thyrotropin receptor antibody.

Authors:  N Inoue; M Watanabe; T Nanba; M Wada; T Akamizu; Y Iwatani
Journal:  Clin Exp Immunol       Date:  2009-01-22       Impact factor: 4.330

8.  Polymorphisms in the TNFA and IL6 genes represent risk factors for autoimmune thyroid disease.

Authors:  Cecília Durães; Carla S Moreira; Inês Alvelos; Adélia Mendes; Liliana R Santos; José Carlos Machado; Miguel Melo; César Esteves; Celestino Neves; Manuel Sobrinho-Simões; Paula Soares
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

9.  Association of TNF-α promoter polymorphism and Graves' disease: an updated systematic review and meta-analysis.

Authors:  Yaqin Tu; Guorun Fan; Tianshu Zeng; Xiong Cai; Wen Kong
Journal:  Biosci Rep       Date:  2018-03-21       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.